In today's episode, we dive deep into the world of gene therapies. Our host, Matt Mancuso, Managing Director and Partner at L.E.K. Consulting's Boston office, is joined by a panel of experts including Ellen Licking, Vice President of Consulting Services and Communications at Real Endpoints; Alex Guth, Managing Director at L.E.K.'s Boston office; and Roger Longman, Chairman of Real Endpoints. Together, they explore the challenges and opportunities surrounding the commercialization of and the access to gene therapies.

From the importance of patient support and access to care to the evolving landscape of value-based agreements, our guests share valuable insights during thought-provoking discussions from a recent gathering of key stakeholders in the gene therapy market. They cover topics such as the impact of combination therapies on efficacy evaluations, the need for infrastructure to enable data sharing, and the potential for risk-sharing structures to address uncertainties in gene therapy outcomes.

Through these conversations, they shed light on the current state of gene therapies, the hurdles that exist in their commercialization, and the innovative strategies being employed to overcome these obstacles. Join us as we explore the intricacies of gene therapies and gain a deeper understanding of the future possibilities and challenges that lie ahead.

Connect with our experts on LinkedIn:
Matt Mancuso: https://www.linkedin.com/in/matthewmancusophd/
Ellen Licking: https://www.linkedin.com/in/ellenlicking/
Alex Guth: https://www.linkedin.com/in/alex-guth-phd/
Roger Longman: https://www.linkedin.com/in/roger-longman-16ba079/

Visit L.E.K. Consulting at https://www.lek.com/